Derbyshire people are urged to take part in Big Butterfly Count to protect endangered species
Wildlife lovers have just a few days left to take part in a project to record butterfly sightings in their garden.
Source: derbyshiretimes.co.uk
📰 Eric Easom News
Page 3 - Eric Easom News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Eric Easom. Real-time updates on events, politics, business and more.
AN2 Therapeutics Initiates Pivotal Phase 2/3 Trial
AN2 is developing epetraborole as a once-daily, orally administered treatment with a novel mechanism of action for patients with NTM lung disease, with an...
Source: globenewswire.com
AN2 Therapeutics Appoints Dr. Mel Spigelman, M.D. to its Board of Directors
/PRNewswire/ -- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases...
Mel Spigelman Eric Easom Medicines Company Mount Sinai School Of Medicine Global Clinical Centers Tb Drug Development Alliance
Source: prnewswire.com
AN2 Therapeutics Appoints Dr. Mel Spigelman, M.D. to its Board of Directors
/PRNewswire/ -- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases...
Mel Spigelman Eric Easom Medicines Company Mount Sinai School Of Medicine Global Clinical Centers Tb Drug Development Alliance
Source: prnewswire.com
With lung drug from Pfizer in hand, AN2 tests IPO waters in turbulent market
Two biotechs are braving the roiling financial markets to raise money for clinical trials. AN2 Therapeutics is preparing for a pivotal test of its boron-based drug candidate for a rare, chronic lung disease. Okyo Pharma also filed IPO paperwork as it looks to advance to the clinic with its dry eye disease drug.
Source: medcitynews.com
AN2 Therapeutics Reports Phase 1b Data for Oral Epetraborole
/PRNewswire/ -- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious...
Source: prnewswire.com
AN2 Therapeutics Provides Regulatory Update and Plan to Initiate Clinical Development for Epetraborole Targeting NTM Lung Disease
/PRNewswire/ -- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious...
Eric Easom Therapeutics Inc Company Investigational New Drug Drug Administration Investigational New Drug Qualified Infectious Disease Product
Source: prnewswire.com
AN2 Therapeutics Nets $80 million for Novel Lung Disease Program
California-based AN2 Therapeutics secured $80 million in Series B funding round to help advance its novel nontuberculous mycobacterial lung disease program.
United States Stephanie Wong Patricia Martin Eli Lillyexecutive Eric Easom Calithera Biosciences Inc
Source: biospace.com
AN2 Therapeutics Closed $80 Million Series B Financing to Advance Novel Nontuberculous Mycobacterial Lung Disease Program
/PRNewswire/ -- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious...
Source: prnewswire.com
AN2 Therapeutics Closed $80 Million Series B Financing to Advance Novel Nontuberculous Mycobacterial Lung Disease Program
/PRNewswire/ -- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious...
Source: prnewswire.com